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Objective: The ideal treatment for hospitalized patients with isolated gastrocnemius and/or soleal venous thrombosis is
unclear. Recommendations range from watchful waiting to full-dose anticoagulation. This study examines the effective-
ness of practice patterns at a single institution as measured by progression of thrombus.
Methods: All consecutive inpatients with a duplex scan diagnosis of isolated gastrocnemius and/or soleal vein clot (no
other thrombotic segments were identified) and where two consecutive duplex studies (Intersocietal Commission for the
Accreditation of Vascular Laboratories laboratory) were available for review were included. Two study groups were
identified. TX group included patients who received anticoagulation treatment (heparin [fractionated or unfractionated],
heparin substitutes, or warfarin) and the NoTX group included those who did not receive anticoagulant. Demographic,
risk factors, comorbidities, length of hospital and intensive care unit stay, ambulatory status, and underlying hyperco-
agulable states were recorded. Thrombus progression rate in the two groups was compared using the 2 test. A
multivariate logistic regression model was used to examine the effect of anticoagulation treatment as well as the above
demographic and clinical factors on the risk of progression.
Results: A total of 141 patients were included in the study, 76 of whom (54%) received anticoagulation. Forty-three
patients (30%) had progression of their venous thrombosis: 33% (25/76) in the TX group and 28% (18/65) in the NoTX
group (P .50, by 2 test). Results frommultivariate logistic regression showed that treatment had no significant impact
on outcome (Odds ratio 1.28, 95% confidence interval: 0.55-3.01; P .57]. Patients with end-stage renal disease (6%),
or stroke (13%) had significantly higher risk of progression (P < .05). None of the other clinical or demographic factors
were significantly associated with the risk of progression.
Conclusion:The results speak to the lack of efficacy of anticoagulation in themanagement of gastrocnemius and/or soleal vein
thrombosis in the hospitalized patient. When measured by thrombus progression, treating these patients without anticoagu-
lation appears to be equally efficacious as subjecting patients to anticoagulant therapy. A prospective, randomized clinical trial
will be an important step in fully addressing this clinical dilemma. (J Vasc Surg 2010;52:1251-4.)The appropriate management of isolated soleal or gas-
trocnemius vein thrombosis (ISGVT) remains undefined.
Unlike venous thrombosis elsewhere, authors differ on
their recommendations for the management of ISGVT.
The most recent Guidelines (8th edition) on Antithrom-
botic and Thrombolytic Therapy by the American College
of Chest Physicians fails to address this entity, further
adding to the uncertainty of its management.1
The goal in managing deep venous thrombosis remains
prevention of thrombus propagation, avoidance of embo-
lization, and reduction of venous insufficiency due to in-
traluminal venous thrombosis. Well-performed studies
have shown, in the absence of treatment, a trivial rate of
propagation of calf vein thrombosis to the popliteal venous
segment with no instances of pulmonary embolization.2-5
Equally well-accepted studies have identified a beneficial
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doi:10.1016/j.jvs.2010.05.102effect of anticoagulation therapy in the treatment of calf
vein thrombosis to prevent venous thromboembolic dis-
ease.6-12
We wanted to understand the practice patterns in our
institution and identify the value and/or limitations of
anticoagulation therapy in patients with ISGVT.
METHODS
Between November 2005 and July 2009, 13,759 inpa-
tient venous duplex examinations were performed in our
Intersocietal Commission for the Accreditation of Vascular
Laboratories (ICAVL) Noninvasive Vascular Laboratory.
We reviewed those studies with ISGVT. Patients with
concomitant venous thrombosis in other venous segments
were excluded. One hundred fifty-eight patients were iden-
tified who had thrombus localized to the gastrocnemius
and/or soleal veins and had a repeat duplex ultrasound
examination within 30 days of diagnosis performed in our
laboratory.
Once identified, these patients’ medical records were
reviewed for demographic and clinical characteristics. Risk
factors for venous thromboembolic disease were recorded,
as were the treatment offered for the diagnosis of ISGVT.
Patients treated with anticoagulation therapy in advance of
the diagnosis of ISGVT (n  17) were excluded from the
study. All patients were required to have a second venous
duplex scan available for review.
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tion administration records and physician order sheets. The
length of stay in an intensive care unit and the overall
hospital length of stay were recorded, as was a careful search
for underlying hypercoagulable states.
A medical doctor and/or a registered vascular technol-
ogist (both members of our ICAVL-accredited laboratory)
reviewed all duplex scans. Those reviewing the studies were
blinded as to the clinical course of the patients and were
able to review the cine loops recorded during the examina-
tion. This method presupposes adequate representation of
the study at the time of the recording. Determination was
made for each pair of patient studies as to the presence of
propagation of thrombus from the original study, resolu-
tion (partial or complete) or no change in the location of
the thrombus from the original diagnostic study.
Propagation was defined using two methods. Initially,
propagation was defined as increased thrombus burden
based on duplex ultrasound reading or review. Thus, ex-
tension within the same vessel, if identifiable, was consid-
ered propagation. Secondarily, propagation was considered
if thrombus appeared on subsequent scans in the tibial,
popliteal, and/or femoral vessels.
Demographic and clinical factors were compared in the
two groups using the t test or 2 test. Thrombus progres-
sion rate in the two groups was compared using the 2 test.
A multivariate logistic regression model was used to exam-
ine the independent effect of anticoagulation treatment on
the risk of progression. The model was adjusted for several
demographic and clinical factors.
RESULTS
One hundred forty-one consecutive patients with
ISGVT were identified from 2005 to 2009 who met the
inclusion criteria for the review. Demographics are shown
in Table I. Seventy-six patients (53.9%) were treated with
anticoagulation (TX), and 65 (46.1%) were not (NoTX).
Table I. Patient demographics
TX (n  76) NoTX (n  65)
Age (mean  SD) 71.5  17.6 years 72.2  14.6 years
Congestive heart failure 15 (20%) 12 (19%)
Atrial fibrillation 19 (25%) 13 (20%)
End-stage renal disease
stage V 6 (8%) 3 (5%)
Recent stroke 9 (12%) 9 (14%)
Chronic obstructive
pulmonary disease 14 (18%) 11 (17%)
Prior deep venous
thrombosis 6 (8%) 6 (9%)
History of cancer 28 (37%) 23 (35%)
Recent surgery 36 (47%) 35 (54%)
Ambulatory 24 (44%) 26 (51%)
Intensive care unit
admission 28 (37%) 24 (37%)
Vascular consult obtained 19 (25%) 19 (29%)
Length of stay (days) 17.3  16.8 14.3  20.7Those treated with anticoagulation received either lowmolecular weight heparin administered on a weight basis to
achieve therapeutic effects or unfractionated heparin on a
weight-based protocol to achieve a partial thromboplastin
time (PTT) of twice normal. The two groups did not differ
significantly in terms of risk factors for venous thrombosis,
length of hospital or critical care unit stay, ambulatory
status, or underlying hypercoagulable states (Table I).
Utilizing the definition of propagation as extension to a
more proximal vessel (ISGVT to tibial, popliteal, and/or
femoral vein), 13% (10/76) in the TX group and 11%
(7/65) in the NoTX group had clot progression (2 .04;
P .83, NS.) Utilizing a more liberal definition of progres-
sion (which simply included increased thrombus burden,
even within the same named vessel[s]), 33% (25/76) of
patients in the TX group had progression of their venous
thrombosis, and 28% (18/65) in the NoTX group demon-
strated duplex documented progression of their thrombo-
sis (2  .45; P  .50, NS) (Table II). Utilizing a multi-
variate regression analysis (Table III), it was further
apparent that anticoagulation treatment had no significant
effect on progression (Odds ratio [OR]  1.28, 95% con-
fidence interval [CI]: 0.55-3.01; P  .57). Higher risk of
progression was significantly associated (P  .05) with
end-stage renal disease (ESRD; 6%, OR  9.35, 95% CI:
1.55-56.54; P .015), or recent stroke (CVA; 13%, OR
3.96, 95% CI: 1.17-13.38; P  .027). Older patients
showed a trend toward a lower risk of progression (OR 
0.79, per 10 years increase, 95% CI: 0.60-1.05; P  .11).
None of the other clinical or demographic factors were
significantly associated with the risk of progression.
DISCUSSION
These results do not support the use of anticoagulation
in the treatment of ISGVT. No advantage could be ascer-
tained in those patients who were administered anticoagu-
lation when compared with those patients left untreated.
Conversely, when complications of anticoagulation were
assessed, no significant difference was noted in those pa-
tients who were treated with full-dose anticoagulation
compared to the nontreatment group.
Much of the literature regarding infrapopliteal venous
thrombosis fails to distinguish between tibial vein throm-
bosis and intramuscular (gastrocnemius and soleal) vein
thrombosis.13,14 However, in a report byMacDonald et al2
where thrombosis was restricted to ISGVT and patients
were not treated with anticoagulation, only 16% of patients
extended their clot proximally; 3% to the level of the
popliteal vein, none to the femoral vein, and the remainder
Table II. Thrombus propagation results
Progression
No progression
or regression
TX group 25 (32.9%) 51 (67.1%)
NoTX group 18 (27.7%) 47 (72.3%)
2  .45; P  .50, NS.to adjacent tibial and peroneal veins. The presence of
(30%
ing 
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extension without the use of anticoagulation in this cohort.
Several studies contradict the current study and that
cited above. Lautz et al8 noted the incidence of venous
thromboembolism after the diagnosis of ISGVT in 27% and
30%, respectively, of patients treated with prophylactic or
no anticoagulation compared with an incidence of 12%
when patients were fully anticoagulated. Gillet et al12
made a similar case for anticoagulation by noting a
relatively high rate of pulmonary embolization associ-
ated with ISGVT. Schwarz et al11 showed a distinct
benefit (when measured by progression of thrombus to
the deep calf veins from the ISGVT, recurrence and
recanalization) when low-molecular-weight heparin was
compared with compression therapy.
This study is a retrospective review, and its results
should be interpreted in that regard. Of our patients, 30.5%
demonstrated progression of thrombus (28% of those not
treated with anticoagulation and 33% treated with full-dose
anticoagulation). There is a higher incidence of progression
in our cohort than in others, which may reflect improved
imaging technology from some of the earlier studies. Alter-
natively, the population in this study consisted of hospital-
ized patients with rather severe illnesses, given the average
length of stay of the two groups exceeded 14 days. This
group of patients has a greater likelihood of developing
venous thrombosis than the outpatient ambulatory patient.
Greater than one-third of all patients had an Intensive Care
Unit (ICU) admission potentially accounting for the iden-
tification of ISGVT based on surveillance protocols utilized
in our ICUs. Indications for initial duplex scanning were
difficult to assess in this retrospective review.
The limitations of this retrospective report are appar-
ent, as are the concerns of inter-observer variability. Our
ICAVL-accredited laboratory does not utilize a protocol
Table III. Multivariate logistic regression model for prog
Factor Mean/%
Anticoagulation 53.9%
Age (per 10 years) 71.8
Gender (male) 47.5%
Body mass index (cm/kg2)a 23.1
Race (vs White)
African American 8.5%
Asian/other 5.7%
Smoking 41.8%
Coronary artery disease 19.3%
Congestive heart failure 21.4%
Hypertension 59.3%
Peripheral vascular disease 4.3%
End-stage renal disease 6.4%
Stroke 12.9%
Liver disease 6.4%
Chronic obstructive pulmonary disease 17.9%
Diabetes 23.6%
Total number of patients  141; number of patients with progression  43
aModel also adjusted for missingness indicator for body mass index (% missfor documenting the exact location of an ISGVT. Whileattempts are made to have repeat studies performed by the
same vascular technologist, the reality of our volume does
not always permit that efficiency. Localization of venous
thrombi within the named vein generally is limited to
identification as “proximal, mid-, and distal segment” of
the specific vein. Thus, propagation is usually only noted
when large changes in clot location (either extension or,
rarely, embolization over short distances) occur. This lim-
itation may result in underestimating clot propagation,
although one would expect this error to occur across both
groups, limiting its effect on the results. Future studies
must operationally define clot location, perhaps relating it
to a distance from a predetermined bony landmark allowing
for a more accurate description of propagation.
Arguments can be made to label propagation only
when thrombus extends to a more proximal vessel. Specif-
ically, a repeat duplex ultrasound that demonstrates throm-
bus in an adjacent tibial or proximal popliteal vein would be
considered propagation, whereas increased thrombus load
confined to the ipsilateral soleal and/or gastrocnemius
veins would not. We chose to consider any increase in
thrombus (either in more proximal vessels or within the
soleal or gastrocnemius veins) as propagation, understand-
ing that this “liberalization” might not be clinically signif-
icant. However, by broadening the definition of propaga-
tion, it would appear that patient safety would be protected
by eliminating a false negative result.
Another study limitation imposed by the retrospective
nature of this report is the lack of uniformity in anticoagu-
lant protocol. While full-dose anticoagulation with an un-
fractionated heparin weight-based protocol was followed in
most patients, some were treated with low molecular
weight heparins or warfarin. Ideally, the nontreatment
group (NoTX) should be compared with a standardized
n
Odds ratio
95% Confidence
interval P value
1.28 (0.55,3.01) 0.57
0.79 (0.60,1.05) 0.11
0.89 (0.39,2.03) 0.78
0.99 (0.92,1.07) 0.81
1.21 (0.28,5.24) 0.80
0.68 (0.10,4.44) 0.69
1.64 (0.65,4.15) 0.30
1.04 (0.35,3.11) 0.95
0.49 (0.15,1.64) 0.25
1.73 (0.81,3.72) 0.16
1.10 (0.12,10.14) 0.94
9.35 (1.55,56.54) 0.015
3.96 (1.17,13.38) 0.027
0.12 (0.01,1.65) 0.11
1.67 (0.56,4.99) 0.36
0.50 (0.15,1.60) 0.24
).
11%) and smoking (14%).ressiotreatment protocol.
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was not evaluated in this report. Masuda et al5 reported a
relatively high incidence (30%) of reflux developing in the
venous system of patients with calf vein thrombosis. While
thromboembolic complications of ISGVT may be immedi-
ately life-threatening, the development of venous insuffi-
ciency is a significantly morbid event. The late development
of venous insufficiency is worth noting when determining
the proper treatment protocol for this disease entity.
The work by Lautz et al8 deserves comment for the
similarity in design to the current study with an equally dis-
similar result. Utilizing a similar approach, this group from
Northwestern University found a significantly higher rate of
venous thromboembolism (VTE) in patients with ISGVT
when these patients did not receive therapeutic anticoagula-
tion. The incidence of VTE in the untreated group (30.6%)
was remarkably similar to that reported here (27.7%). Inter-
estingly, this group demonstrated a 4% incidence across all
groups of pulmonary embolization from ISGVT.
The results of this report, at a minimum, raise questions
regarding the value of anticoagulation in the management
of ISGVT. There were no hemorrhagic complications in
the TX group, thus refuting the argument against antico-
agulant therapy as a risk factor for bleeding. Conversely,
there were no thromboembolic episodes in the NoTX
group, thereby arguing against the use of anticoagulation
in the management of ISGVT.
Our current bias is to treat ISGVT “expectantly.” We
recommend early ambulation when feasible, use of a se-
quential compression device when patients are in bed, and
repeat duplex ultrasound examination within 72 hours,
preferably by the same technologist who performed the
initial study. Any sign of propagation to the next named
vein warrants full anticoagulation therapy with heparin.
Patients with end-stage renal disease or those with a recent
cerebrovascular event were more likely to propagate their
thrombus than others, identifying a subset that might
benefit from anticoagulation therapy for ISGVT.
Masuda, at the 2010 American Venous Forum, sug-
gested the need for a randomized controlled trial.15 How-
ever, if treatment with full-dose anticoagulation is to be
avoided, it is imperative that follow-up duplex examination
be available and utilized. We would also advocate the use of
early ambulation and sequential compression device use on
a nonaffected extremity. Any sign of propagation warrants
conversion to full-dose anticoagulation.
Therefore, our current practice recommendations for
ISGVT would include early ambulation, sequential com-
pression devices on an unaffected extremity (taking care
that these do not impede the patient’s impetus to ambu-
late), and anti-inflammatory medications if possible. We do
NOT recommend anticoagulation in the absence of prop-
agation, and we strongly suggest repeat duplex examina-
tions with careful notation of proximal extent of the throm-
bosis within the soleal and/or gastrocnemius veins. We
accept that there will be those patients whose physicians
will demand treatment with anticoagulation. Based on our
data, we would still recommend careful follow up of thesepatients, as propagation rates remain high even in the
presence of full-dose anticoagulation. We firmly support an
effort to engage a randomized clinical trial to adequately
assess this clinical question.
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